Overview
Nuevocor has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for NVC-001.
About NVC-001
- NVC-001 is an adeno-associated virus (AAV)-based gene therapy and is the first treatment of its kind aimed at addressing the root mechanobiological cause of LMNA DCM.
- The company plans to start a Phase 1/2 clinical trial, which will be an open-label, dose-escalation study involving adult patients with the condition.
About the condition: LMNA DCM
- LMNA DCM is caused by mutations in the LMNA gene, which encodes the lamin A/C protein.
- This protein plays a crucial role in maintaining the nuclear envelope and regulating gene activity in heart cells.
- Damage caused by these mutations can lead to weakening of the heart, irregular heartbeats, and eventual heart failure.
- The condition affects around 100,000 people across the United States and Europe.
The therapy target- The therapy is designed to treat LMNA-related dilated cardiomyopathy (LMNA DCM), a rare genetic condition that affects the heart muscle.
NVC-001 efficacy
- NVC-001 has been developed to reduce mechanical stress on the cell nucleus and restore nuclear envelope stability, which is often disrupted in individuals with LMNA DCM.
- In preclinical studies, the treatment showed positive results, including improved heart function and survival.
- NVC-001 will be delivered as a single intravenous infusion across different dosage groups.
The upcoming trial
The upcoming 52-week clinical trial will be conducted at multiple centres and will assess the safety, tolerability, and early effectiveness of the therapy.
